Mashall et al. [10] designed and constructed a fusion protein of anti-ErbB2 scFv and CD28; this fusion protein could be used for targeting of breast cancer cells positive for ErbB2 expression, providing a stimulatory signal for activation of T cells Report of Vaishampayan et al. [11] provided a strong rationale for developing phase II trials to determine whether ATC armed with Her2Bi (aATC) are effective for treating castrate resistant prostate cancer. This evidence concerns the gene ERBB2 and prostate cancer.